[Federal Register Volume 69, Number 153 (Tuesday, August 10, 2004)]
[Notices]
[Pages 48522-48523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-18178]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952(a)(2)(B) authorizing the importation 
of such a substance, provide manufacturers holding registrations for 
the bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on June 8, 2004, JFC Technologies, LLC, 100 West Main Street, P.O. 
Box 669, Bound Brook, New Jersey 08805, made application by letter to 
the Drug Enforcement Administration (DEA) for registration as an 
importer of Meperidine-Intermediate-B (9233), a basic class of 
controlled substance listed in Schedule II. The company plans to import 
the basic class of controlled substance for the production of other 
controlled substances for distribution to its customers.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such comments or objections or requests for hearing may be 
addressed, in quintuplicate, to the Deputy Assistant

[[Page 48523]]

Administrator, Office of Diversion Control, Drug Enforcement 
Administration, United States Department of Justice, Washington, DC 
20537, Attention: DEA Federal Register Representative (CCD) and must be 
filed no later than September 9, 2004.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975 (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substances in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), 
(c), (d), (e), (f) are satisfied.

    Dated: July 23, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-18178 Filed 8-9-04; 8:45 am]
BILLING CODE 4410-09-M